Joint venture partnering is a specific type of deal whereby the parties to the deal agree to form a legal third party entity, normally under the joint control of the parties to the deal, to jointly fund and develop a compound, product or technology. Read the full story

The Global Joint Venture Partnerships in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the joint venture partnering agreements entered into by the worlds leading healthcare companies.

This new 1st edition, includes:

• Trends in joint venture deals
• Joint venture agreement structure
• Joint venture contract documents
• Top joint venture deals by value
• Most active joint venture dealmakers
• Comprehensive directory of joint venture deals since 2009

This report provides details of the latest joint venture agreements announced in the pharmaceutical, biotechnology and diagnostic sectors.

The report provides details of joint venture agreements from 2009 to end of August 2014.

The report provides a detailed understanding and analysis of how and why companies enter joint venture deals.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all joint venture deals announced since 2009 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual co-promotion and co-marketing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

BioLife Solutions announced the formation of a joint venture under the brand name of biologistex Cold Chain Management. Read the full story

Bristol-Myers Squibb and Allied Minds announced today the formation of a joint research institute to foster the research and development of pharmaceutical compounds. Read the full story

New Zealand’s Fonterra and Abbott, the US big pharma and health care giant are to develop a dairy farm hub in China. Read the full story

Big pharma, Roche said it will partner with Inception Sciences and Versant Ventures on a new company to develop therapies for patients with multiple sclerosis. Read the full story

The recently disclosed failed bid by Pfizer to acquire bigpharma rival AstraZeneca has analysts predicting several outcomes as M&A fever sweeps the pharma sector Read the full story

Process Systems Enterprise and Pfizer, (big pharma), have formed the Systems-based Pharmaceutics Alliance. Read the full story

JLL Partners and Royal DSM have announced a collaboration to form a new pharma company. Read the full story

Abbott is partnering with the non-profit organization Music Saves Lives for a joint venture to encourage young adults to consider becoming life-long donors. Read the full story